Ionizable compounds and compositions and uses thereof

US10167253B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10167253-B2
Application numberUS-201615191511-A
CountryUS
Kind codeB2
Filing dateJun 23, 2016
Priority dateJun 24, 2015
Publication dateJan 1, 2019
Grant dateJan 1, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound comprising the structure shown in Formula I wherein R 1 and R 2 are R 1 =CH 2 (CH 2 ) n OC(═O)R 4 R 2 =CH 2 (CH 2 ) m OC(═O)R 5 wherein n and m are each independently from 1 to 2; and R 4 and R 5 are independently for each occurrence a C(12-20) alkyl group, or a C(12-20) alkenyl group; wherein R 3 is selected from wherein each R 6 is independently selected from H, alkyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkoxy, and aminoalkyl; each R 7 is independently selected from H, alkyl, hydroxyalkyl, and aminoalkyl; Q is O or NR 7 . 2. The compound of claim 1 , wherein alkyl is C(1-6)alkyl, hydroxyalkyl, is hydroxyl[C(1-6)alkyl], and aminoalkyl is amino[C(1-6)alkyl]. 3. The compound of claim 1 , R 4 and R 5 are independently for each occurrence a C(14-18) alkyl group, or a C(14-18) alkenyl group. 4. The compound of claim 1 , wherein Q is O. 5. The compound of claim 1 , having a structure selected from 6. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 7. The composition of claim 6 , wherein the composition comprises nanoparticles. 8. A pharmaceutical composition comprising a compound of claim 1 , an active agent, and a pharmaceutically acceptable carrier. 9. The composition of claim 8 , wherein the compound is from 15 mol % to 40 mol % of the lipids of the composition. 10. The composition of claim 8 , wherein the composition comprises nanoparticles. 11. The composition of claim 8 , wherein the active agent is one or more RNAi molecules. 12. The composition of claim 8 , wherein the active agent is one or more RNAi molecules selected from small interfering RNAs (siRNA), double stranded RNAs (dsRNA) that are Dicer substrates, microRNAs (miRNA), short hairpin RNAs (shRNA), DNA-directed RNAs (ddRNA), Piwi-interacting RNAs (piRNA), repeat associated siRNAs (rasiRNA), and modified forms thereof. 13. A composition for use in distributing an active agent for treating a condition or disease in a subject, the composition comprising a compound of claim 1 , a structural lipid, a stabilizer lipid, and a lipid for reducing immunogenicity of the composition. 14. The composition of claim 13 , wherein the active agent is one or more RNAi molecules and the composition comprises nanoparticles that encapsulate the RNAi molecules. 15. The composition of claim 14 , wherein the active agent is one or more RNAi molecules selected from small interfering RNAs (siRNA), double stranded RNAs (dsRNA) that are Dicer substrates, microRNAs (miRNA), short hairpin RNAs (shRNA), DNA-directed RNAs (ddRNA), Piwi-interacting RNAs (piRNA), repeat associated siRNAs (rasiRNA), and any modified forms thereof. 16. A method for ameliorating or treating a disease or condition in a subject in need comprising administering to the subject a composition of claim 8 .

Assignees

Inventors

Classifications

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • A61K9/127Primary

    Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title

  • C07D207/12Primary

    Oxygen or sulfur atoms · CPC title

  • without P—C bonds · CPC title

  • Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10167253B2 cover?
This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and…
Who is the assignee on this patent?
Nitto Denko Corp
What technology area does this patent fall under?
Primary CPC classification A61K9/127. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).